Physician profile
Jay B Adler
NPI 1619930641
$3,924.19
in general payments reported to CMS, 2019-2025
32 companies · $858 in 2025
The $858 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $673 · 2020: $285 · 2021: $390 · 2022: $622 · 2023: $613 · 2024: $485 · 2025: $858.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,946 · Education: $9.24.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,945.76 |
| Education | $9.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $898.71 | 2019-2025 | Stelara, Simponi Aria, Simponi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $615.20 | 2019-2025 | Xifaxan, Plenvu, Trulance |
| Abbvie INC. | $491.35 | 2019-2025 | Linzess, Viberzi, Creon |
| Intercept Pharmaceuticals, INC. | $310.67 | 2019-2025 | Ocaliva |
| Celgene Corporation | $216.13 | 2021-2024 | Zeposia |
| Lilly USA, LLC | $192.42 | 2024-2025 | Omvoh |
| Gilead Sciences, INC. | $122.41 | 2019-2020 | |
| Madrigal Pharmaceuticals | $102.96 | 2024-2025 | Rezdiffra, Resmetirom |
| Genzyme Corporation | $98.50 | 2025 | |
| Redhill Biopharma INC. | $76.84 | 2020-2022 | |
| Ardelyx, INC. | $76.05 | 2022-2025 | Ibsrela |
| Regeneron Healthcare Solutions, INC. | $74.60 | 2025 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $71.08 | 2019-2022 | |
| Daiichi Sankyo INC. | $70.52 | 2021-2022 | |
| Boston Scientific Corporation | $52.69 | 2023 | Resolution 360 Clip |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shionogi INC | $50.06 | 2019 | |
| Pfizer INC. | $43.14 | 2024 | |
| Aimmune Therapeutics, INC. | $39.77 | 2024-2025 | Zenpep |
| Intra-Sana Laboratories | $37.72 | 2025 | Reltone 200 Mg, Glycate, Reltone 400 Mg |
| Nestle Healthcare Nutrition INC. | $37.70 | 2020-2021 | |
| Ironwood Pharmaceuticals, INC | $33.75 | 2019-2020 | |
| Phathom Pharmaceuticals, INC. | $31.70 | 2024 | Voquezna |
| Evoke Pharma, INC. | $31.54 | 2020-2023 | Gimoti |
| Novo Nordisk INC | $28.79 | 2025 | Wegovy |
| Astrazeneca Pharmaceuticals Lp | $21.53 | 2023 | |
| Cumberland Pharmaceuticals, INC. | $17.38 | 2020 | |
| Alfasigma USA, INC. | $16.32 | 2020 | |
| Allergan, INC. | $14.98 | 2019 | |
| Endo Pharmaceuticals INC. | $14.64 | 2019 | |
| Qol Medical, LLC | $13.68 | 2021 | |
| Merck Sharp & Dohme LLC | $12.12 | 2021 | |
| Janssen Pharmaceuticals, INC | $9.24 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jay Adler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.